Get the content you want anytime you want.
REGISTER NOW | SIGN IN

The Contagion® Healthcare Associated Infections (HAI) specialty page provides HAI-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

HEALTHCARE-ASSOCIATED INFECTIONS (HAI) VIDEOS - Page 2

<i>Pseudomonas aeruginosa</i>: Current & Future Treatment Options
Marin H. Kollef, MD, discusses treatment options for Pseudomonas aeruginosa.
<i>Clostridium difficile</i>: The Role of Bezlotoxumab
Lawrence J. Brandt, MD; Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, introduce bezlotoxumab, an additional treatment option that is in the pipeline for Clostridium difficile; explore how it works; and suggest which types of patients may be most appropriate to receive this treatment.
What Are the Next Steps for Ridinilazole?
Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.
Community Sources of <i>Clostridium difficile</i>
Following a general discussion on risk factors for Clostridium difficile, Lawrence J. Brandt, MD; Erik Dubberke, MD; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, distinguish which factors increase the likelihood for community onset.
Governmental Intervention Needed to Ensure Hospital Mattresses Get Cleaned Appropriately
Edmond Hooker, MD, DrPH, stresses that the FDA and the CDC need to intervene to ensure that hospital mattresses get cleaned appropriately.
Understanding What Motivates Health Care Works Crucial to Reducing <i>C. diff</i> Rates
Barley Chironda, RPN, CIC, stresses that understanding what motivates health care workers’ actions is crucial for reducing C. diff rates in hospitals.
Costs of Care Considerations in <i>Clostridium difficile</i>
In this segment, Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, remark on the financial burden of Clostridium difficile, highlighting recurrent disease as a contributing factor and, consequently, considering the cost-effectiveness of treating appropriate candidates with fidaxomicin.
Why Are <i>Pseudomonas</i> Infections Getting Harder to Treat?
Marin H. Kollef, MD, explains why Pseudomonas infections are getting harder to treat.
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.